MedPath

Atosiban an intravenous medication as a labour repressant (tocolytic) to halt premature labor.

Phase 4
Completed
Conditions
Health Condition 1: O600- Preterm labor without delivery
Registration Number
CTRI/2017/03/008065
Lead Sponsor
Zuventus Healthcare Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
440
Inclusion Criteria

1.Women >=18 years of age

2.Gestational age from 24 until 33 completed weeks which has been documented by a definite LMP or sonography in the first trimester

3.Women with preterm labor. The diagnosis of preterm labor requires the presence of >= 4 uterine contractions over 30 minutes, each lasting at least 30 seconds, and documented cervical change. Criteria for cervical changes are defined as follows:

a.Nulliparous women: a single cervical examination demonstrating dilatation of 0 cm to 3 cm and effacement of at least 50%

b.Multiparous women: a single cervical examination demonstrating dilatation of 1 cm to 3 cm and effacement of at least 50%.

Exclusion Criteria

1.Women with any of the following:

a.Chorioamnionitis

b.Preterm rupture of membranes

c.Vaginal bleeding

d.Eclampsia and severe pre-eclampsia requiring delivery

e.Intrauterine growth restriction

f.Intrauterine fetal death

g.Congenital or acquired uterine malformation

h.Severe placental insufficiency

i.Placenta previa and abruptio placentae

2.Fetal distress

3.Women who are otherwise judged inappropriate for inclusion in the study by the investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Proportion of women remaining undelivered at 72hrs after start of atosiban treatment <br/ ><br>2. Evaluation of time gained in utero after initiation of treatment <br/ ><br>3. Percentage reduction in uterine contractions from baseline <br/ ><br>4. Proportion of women re-treated with atosiban <br/ ><br>5. Proportion of women re-treated with alternative tocolytic agent <br/ ><br>Timepoint: till the time of delivery
Secondary Outcome Measures
NameTimeMethod
1. Proportion of maternal and fetal adverse events reported during the study periodTimepoint: till the time of delivery
© Copyright 2025. All Rights Reserved by MedPath